E-viri
Recenzirano
-
Dolušić, Eduard; Frédérick, Raphaël
Expert opinion on therapeutic patents 23, Številka: 10Journal Article
The inhibition of indoleamine 2,3-dioxygenase (IDO) has emerged as a key area in cancer immunotherapy in the past decade. Despite the large variety of potential inhibitors screened so far, the number of active scaffolds remains limited. All relevant patent literature published between 2008 and 2012 is reviewed. Representative examples are given for each patent and/or class of compounds along with data (if available) on their inhibitory activity. The presentation is deepened by additional data published in peer-reviewed literature. Key events that stimulated the search of IDO inhibitors are presented. To date, however, the number of available scaffolds remains limited with only one confirmed inhibitor (from Incyte Corp.) in the clinic. Major challenges in the search for IDO inhibitors are discussed as well as the relevance of selectivity of IDO inhibition versus inhibition of tryptophan 2,3-dioxygenase.
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.